Sanofi Benefits From Stockpiling In Q1, Predicts Long-Term Uplift In Supplements Demand
Executive Summary
Sanofi benefits from coronavirus-triggered stockpiling in Q1, with Consumer Healthcare head Alan Main suggesting the pandemic may have turned more consumers into regular dietary supplement users
You may also be interested in...
Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines
Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.
Sanofi Names Estée Lauder Exec As Global Consumer Healthcare Head
President of Estée Lauder's Origins business Julie Van Ongevalle will take the reins of Sanofi's global Consumer Healthcare business from September. The French firm is banking on Van Ongevalle's digital and brand-building experience to take the business to the next level.
GSK Enters Race For OTC COVID-19 Test With Mammoth Biosciences As Partner
GSK partners with biotech firm Mammoth Biosciences to develop a home-use OTC nasal swab test for COVID-19 that works in less than 20 minutes. Mammoth says the firms will seek an FDA emergency use authorization for the test, roll it out first to clinics and will seek approval for OTC sales.